OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Conventional and robotic automation inside closed systems reduces risk.
Evolving equipment designs meet the needs of continuous processing techniques.
Stability programs for biologics are far more complex than small-molecule drugs.
Reformulation strategies are useful tools for more than just stretching out return on investment.
Almost half of pharmaceutical industry profits continue to come from biopharmaceuticals.
Next Big COVID Challenge: Vaccines for Little Kids
Pharma strategizes to reduce its environmental footprint while optimizing output.
October 12, 2021
AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.
Supernus will acquire Adamas’ Parkinson's disease treatment portfolio through a $400 million acquisition.
October 11, 2021
MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, signed an agreement with Cellecta to license its genome-editing tool.
October 08, 2021
The approval of ChemoCentryx’s Tavenos (avacopan) provides a new treatment for active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
AstraZeneca’s tezelpelumab was granted orphan drug designation by FDA for the treatment of eosinophilic esophagitis.
Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.
Pfizer and BioNTech’s request would make them the first vaccine accessible to individuals under the age of 12.
Moderna’s new facility is expected to produce 500 million vaccine doses per year.
October 07, 2021
FDA’s emergency use authorization will double rapid at-home COVID-19 testing capacity.
The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.